Actively Recruiting
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Led by Sacramento Pediatric Gastroenterology · Updated on 2016-11-15
200
Participants Needed
1
Research Sites
939 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
CONDITIONS
Official Title
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal disorder or who are undergoing upper or lower endoscopy.
- Persons who have primary sclerosing cholangitis or biliary atresia who are good candidates for vancomycin therapy.
You will not qualify if you...
- Patients that have taken antibiotics and/or immunomodulators within the last 3 months.
- Females who are pregnant.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sacramento Pediatric Gastroenterology
Sacramento, California, United States, 95841
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here